A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)

Le, X., Patel, J. D., Shum, E., Baik, C., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R., Elamin, Y. Y., Tu, J., Blumenschein, G., Zhang, J., Gibbons, D., Gay, C., Mohindra, N. A., Chae, Y., Boumber, Y., Sabari, J., … Heymach, J. V. (2024). A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00533
Authors:
Xiuning Le
Jyoti D Patel
Elaine Shum
Christina Baik
Rachel E Sanborn
Catherine A Shu
Chul Kim
Mary Jo Fidler
Richard Hall
Yasir Y Elamin
Janet Tu
George Blumenschein
Jianjun Zhang
Don Gibbons
Carl Gay
Nisha A Mohindra
Young Chae
Yanis Boumber
Joshua Sabari
Rafael Santana-Davila
Shane Rogosin
Benjamin Herzberg
Ben Creelan
Bruna Pellini
Tawee Tanvetyanon
Simon Heeke
Mike Hernandez
Jhanelle E Gray
Andreas Saltos
John V Heymach
Affiliated Authors:
Catherine A Shu
Benjamin Herzberg
Publication Type:
Article
Unique ID:
10.1200/jco.24.00533
PMID:
Publication Date:
Data Source:
PubMed

Record Created: